leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The goal of this study was to define the potential to use canine lymphoma and leukemia as suitable models to refine therapeutic approaches targeting the interleukin-2 receptor (IL-2R).
|
11924909 |
2002 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results suggest that although reduction in the proportion of leukaemia in contaminated marrow can be detected after incubation with IL-2 for 24 h, complete elimination of minimal residual disease requires longer incubation times.
|
7533866 |
1995 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-2-dependent ATL cell lines with phenotypes differing from the original leukemia cells.
|
1861543 |
1991 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of interleukin 2 receptor (IL2R) in hematological malignancies has been utilized to target leukemia.
|
26984209 |
2016 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Concentration of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia after cessation of chemotherapy.
|
15152368 |
2004 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells.
|
1698543 |
1990 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We believe our results provide important mechanistic insights for the potential use of IL-2-expanded CB-derived NK cells for adoptive immune therapy in leukemia.
|
20664358 |
2010 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-2-dependent clones established from the DN alphabeta T cell population in the PEC of IL-2 receptor alpha-chain transgenic B6 mice exhibited potent cytotoxicity against a series of B cell lineage leukemias and myelomas, such as CD5+BCL1 and MOPC, without affecting NK-susceptible targets.
|
8892624 |
1996 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.
|
25109334 |
2015 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Four aspects are discussed: (i) the generalized immune activation induced by the systemic administration of cytokines, in particular, interleukin-2; (ii) the specific T cell-mediated reactions against tumour cells through the recognition of tumour-associated molecules, 1) and tyrosinase proteins described in melanomas, and minor histocompatibility antigens in the setting of allogenic bone marrow transplantation for leukaemia; (iii) the potentially significant but still hypothetical immune-mediated recognition of molecules either tumour-associated or transformation-related (including altered oncogenic proteins); and (iv) the role of co-stimulatory molecules in the induction of tumour-specific immunity.
|
8535054 |
1995 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Earlier we have shown that interleukin-2 (IL-2)-activated MNC from cord blood have significant cytotoxic activity against human leukemia and breast cancer cells in vitro and in vivo, compared to MNC from peripheral blood.
|
12494899 |
2003 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In a phase IV trial (Re:Mission Trial, NCT01347996, http://www.clinicaltrials.gov ) 84 patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received ten consecutive 3-week cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose interleukin-2 (IL-2) to prevent relapse of leukemia in the post-consolidation phase.
|
28721449 |
2017 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interleukin 2 (IL 2) receptor (IL 2-R) is constitutively expressed on T cell lines established from the patients with adult T cell leukemia (ATL), which is a human T cell leukemia lymphoma virus (HTLV-1)(+) T4(+)-leukemia endemic in Japan, the United States, and other countries.
|
2999237 |
1985 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the effects of physiologically achievable concentrations of butyrate on IL-2R expression could be exploited to enhance the susceptibility of intermediate and low-affinity IL-2R expressing leukemia cells to DAB(389)IL-2.
|
12443879 |
2002 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines - Construction and characterization.
|
20580754 |
2010 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Possible explanations for these outcomes include immunologic response to sepsis by a leukemia-specific T-cell response or the release of various cytokines, such as tumor necrosis factor and interleukin-2, during infections.
|
22627572 |
2012 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phorbol ester induces interleukin-2 receptor on the cell surface of precursor thymocyte leukemia with no rearrangement of T cell receptor beta and gamma genes.
|
2822168 |
1987 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of human T-cell leukaemia virus type I and associated antigens, and interleukin-2 and receptor in lymph nodes of adult T-cell leukaemia/lymphoma.
|
7812510 |
1994 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
One agent, containing human interleukin-2 and truncated diphtheria toxin (denileukin diftitox), has been approved for use in cutaneous T-cell lymphoma, and has shown activity in other hematologic malignancies, including leukemias and lymphomas.
|
19344187 |
2009 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data presented the possibility that lck gene product may be one of the intervening molecules which transduce the signal from the IL-2R into the cell interior, and play an important role in the pathophysiology of adult T cell leukemia, especially in the transition of these leukemias from the IL-2-dependent stage to IL-2-independent one for their growth.
|
2786034 |
1989 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
To search for these molecules we aligned IL-2 regulated genes detected by Affymetrix gene expression microarrays with the STAT5 cistrome identified by chip-on-ChIP analysis in an IL-2-dependent human leukemia cell line, Kit225.
|
23451206 |
2013 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-1-induced production of IL-2 and IFN-gamma in subclones of human T-cell derived leukaemia HSB.2 cells: regulation by phytohaemagglutinin-mediated (poly)phosphoinositide breakdown and cyclic AMP.
|
2172158 |
1990 |
leukemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
|
17500047 |
2007 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
12473581 |
2002 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-2 (IL-2) and IL-15 play pivotal roles in T cell activation, apoptosis, and survival, and are implicated in leukemias and autoimmune diseases.
|
31570576 |
2019 |